As a premier European life sciences hub, Belgium is a global powerhouse renowned for its densely integrated ecosystem of pharmaceutical manufacturing, biotechnology innovation and world-class academic research. Often referred to as "Biotech Valley," the country serves as a strategic gateway for clinical trials, benefiting from a streamlined regulatory framework that accelerates the path from lab to patient.
Belgium's pharmaceutical industry is a top-tier global exporter, particularly dominant in vaccine development, oncology and advanced therapy medicinal products (ATMPs) like cell and gene therapies.
The medical device sector is equally dynamic, with a strong focus on healthcare innovation in digital health, medical imaging and in vitro diagnostics. This progress is fueled by a collaborative network of leading research universities, such as KU Leuven and UGent, alongside specialized life sciences clusters like Flanders.bio and BioWin. International investors are drawn to the region's high-density R&D intensity, supported by attractive tax incentives and a highly skilled workforce.
Furthermore, Belgium's advanced cold-chain logistics and specialized pharmaceutical infrastructure ensure it remains a critical link in the global life sciences supply chain.
As the sector shifts toward personalized medicine and AI-driven drug discovery, Belgium continues to pioneer breakthroughs that define the future of global healthcare.
Belgium's healthcare system is based on mandatory health insurance and a hybrid model of public and private providers. Healthcare expenditure reached approximately €41.3 billion for 2026 (roughly 11% of GDP). Belgium maintains 5.4 hospital beds per 1,000 people, which is higher than the OECD average. Leading research institutions include KU Leuven, Ghent University and the Flanders Institute for Biotechnology (VIB).
Belgium's life sciences R&D funding is decentralized across Flanders, Wallonia and the Brussels-Capital Region. In Flanders, VLAIO supports biotech and pharma innovation through R&D grants and investment subsidies spanning feasibility to development. Wallonia's SPW Recherche funds industrial research and experimental development, including a dedicated €81 million innovation partnership for advanced therapy medicinal products (ATMPs). In Brussels, Innoviris backs life sciences and health innovation with project co-funding, R&D programs and innovation vouchers.
Belgium's biotech firms had a combined market capitalization of around $46.7 billion (€40.1 billion) in 2023, the second-highest in Europe behind Denmark. However, VC inflows slowed in 2023, with total value of deals falling 55% year-on-year, according to the Global Innovation Index 2024.
The Wallonia life sciences ecosystem includes global players such as UCB, Janssen and GSK, supported by clusters like the Brussels South Charleroi Biopark, Louvain-la-Neuve and Liège. Belgium's pharmaceutical ecosystem includes 29 of the world's top 30 pharma companies, including Johnson & Johnson and Pfizer, and as of 2022, employed over 30,000 people in the industry
Belgium's medtech sector generates around $4 billion (€3.4 billion) annually across 250 companies, employing 16,750 people with approximately 10.3% annual turnover growth. Key players include IBA, Baxter, Johnson & Johnson, Mölnlycke and CooperVision. Wallonia also drives innovation in digital health and AI-enabled medtech (e.g., MedReSyst).
Belgium ranked #2 in the European Economic Area (EEA) for per-capita commercial trial starts in 2023 (1.84 per 100,000), but the European Federation of Pharmaceutical Industries and Associations (EFPIA) notes a decline in immunization-trial starts since 2018 and stakeholder concerns about longer approval timelines post-EU Clinical Trials Regulation (CTR). Belgium ranks in the top 3 in Europe for clinical trials, with around 629 applications submitted between January 2022 to January 2023. About 80% of trial requests originate from biopharma companies; in 2021, Belgium accounted for 20% of Europe's cancer-related trials.
Brussels, Belgium
Life sciences are Belgium's leading export category, with biopharmaceutical exports valued at around $21.65 billion (€18.6 billion). Nuclear medicine also contributes about $262 million (€225 million) in added value, supporting 5,000 jobs nationally. Belgium is the 4th largest global exporter of pharmaceutical goods, with exports rising from approximately $65.8 billion (€56.5 billion) in 2022 to an estimated $69.8 billion (€60 billion) in 2023. The pharmaceutical industry also drives private R&D with around $1.75 billion (€1.5 billion) invested annually, representing 40% of all corporate R&D spend.
According to the Global Innovation Index 2024, Belgium had 6,964 researchers per million people in 2022, ranking 7th worldwide. In Wallonia, the sector employed over 20,000 people across more than 260 companies, with 11,000 researchers and an average 4.5% annual employment growth between 2005 and 2022. As of 2022, Belgium's biopharma sector directly employed 43,000 people, and including suppliers and supporting industries, the total impact rises to over 137,000 jobs, roughly three times the European average per capita.
Belgium is a recognized vaccine hub, exporting around $320.1 million (€275 million) worth of vaccines and medicines daily (17% of total exports). GSK Belgium, with 9,000 employees, delivers 1.5 million vaccine doses each da
Belgium ranks 24th in the Global Innovation Index 2024 (13th for Human Capital & Research, 4th for R&D spending at 3.43% of GDP, 7th for researcher density). The Brussels-Antwerp region is listed among the world's top 100 science and tech clusters.
Claim Profile to Update Website
Claim Profile to Update Contact Information
Claim Your Profile to Add Related Links
Claim Your Profile to add downloadable documentation
https://pharmaville.com/wp-content/uploads/2026/02/Pharmaville-Belgium-references.pdf
